author-photo

Chenxiang Li

Merck & Co.

2

Papers

12

Citations

Citation Trend

Filter By

Papers (2) Sort By

Journal Conference Others

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (11)
KEYNOTE-B61: Open-label phase 2 study of pembrolizumab in combination with lenvatinib as first-line treatment for non-clear cell renal cell carcinoma (nccRCC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)